Message :
Required fields
RARITAN, N.J., April 13, 2021 /PRNewswire/ Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world s largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020. The CE Mark allows for more convenient sample collection and expanded viral transport media. Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these back-to-normal measures, said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. Ortho s customers continue to trust its COVID-19 testing solutions including the updated antigen test to efficiently meet the demand for accurate mass testing and fast, trusted results.
(0)
RARITAN, N.J., April 13, 2021 /PRNewswire/ Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world s largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS SARS-CoV-2 Antigen Test, initially launched in October 2020. The CE Mark allows for more convenient sample collection and expanded viral transport media. Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these back-to-normal measures, said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. Ortho s customers continue to trust its COVID-19 testing solutions-including the updated antigen test-to efficiently meet the demand for accurate mass testing and fast, trusted results.
Ortho s VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(1)
Molecular Transport Medium at the price of VTM
BANGALORE, INDIA, Dec 15, 2020 - (ACN Newswire) - Azooka Labs, a leading safe fluorophore company with specialization in Molecular Biology products, reveals its first range of novel COVID-19 diagnostics products. RNA Wrapr is a molecular transport medium for COVID-19 sample collection, developed as part of the COVID-19 response team from Indian Institute of Science.
Molecular Transport Media that inactivates the Coronavirus immediately. Not only that! Azooka s RNA Wrapr does not require dry ice for storage and can be processed until a week. A storage medium for COVID-19 that is safe, easy to use and affordable.